Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Express Scripts Includes New Cholesterol-lowering Drugs on its National Preferred Formulary
October 07, 2015.
Express Scripts (St. Louis, MO) announced yesterday that it will include two new cholesterol-lowering drugs on its National Preferred Formulary.
Sanofi's Praluent and Amgen's Repatha are the first PCSK9 inhibitors to be approved by FDA. Dr. Steve Miller, Senior Vice President and Chief Medical Officer of Express Scripts, commented: "Since these new medications were approved a few months ago, our pharmacy experts have worked with medical professionals and our plan sponsors to ensure these drugs are used specifically by patients who will benefit the most. We are pleased to include both drugs on our National Preferred Formulary, and to put innovative medicines within reach of patients who truly need them."
Recent Videos
Related Content
